Pembrolizumab,Gemcitabine
Merck
[' gem ', 'pembro', 'bladder', 'mibc']
ph 2 trial long-term outcomes of pembro + gem and concurrent hypofx rt as bladder sparing rx for mibc #asco23 n=54, 88% comp all rx 11%: salvage cystectomy med f/u 23 months: 22% tumor recurrences 2-yr bidfs 71%, mfs 78%, os 83% 24%: 
Uro Onc @GACancerCenter | Assoc Prof, Resident PD, and Ronald W. Lewis, MD Chair of Uro Educ @mcg_urology | #mentalhealth research | @urotoday Contributor